Table 2.

Significant variant SNPs of Anti-CGRP monoclonal antibody therapy efficacy in our chronic migraine cohort

Variant SNP ID	CHR	BP	Ref	Alt	BETA	SE	L95	U95	P-Valuea	Type	Gene	MAFb	TWc	EASd
rs116870564	11	40,698,550	G	A	-0.551	0.087	-0.721	-0.381	6.65E-09	intronic	LRRC4C	0.009	0.026	0.027
rs75244870	3	58,551,849	T	C	-0.518	0.082	-0.679	-0.358	6.92E-09	intergenic	ACOX2(Up); FAM107A (Down)e	0.019	0.017	0.012
rs56216870	8	124,758,943	C	T	-0.518	0.084	-0.683	-0.352	1.77E-08	intergenic	MTSS1 (Up); MIR4662B (Down)	0.037	0.055	0.093
rs12938101	17	50,298,471	A	T	-0.483	0.081	-0.641	-0.324	3.85E-08	intergenic	TMEM92-AS1(Up); XYLT2 (Down)	0.037	0.040	0.034
rs74655790	2	23,769,060	C	T	-0.509	0.086	-0.677	-0.341	4.24E-08	intronic	ATAD2B	0.009	0.019	0.013
rs149540851	8	106,592,971	C	A	-0.509	0.086	-0.677	-0.341	4.24E-08	intronic	OXR1	0.009	0.009	0.030

^a Filter by p < 10^− 7.

^b Minor Allele Frequency in this study.

^c Minor Allele Frequency in Taiwan Biobank.

^d Minor Allele Frequency in East Asian from 1000 genome.

^e Up: Upstream. Down: Downstream.